ArticleTranslational cancer research2026
Integrative analysis reveals the role of SUMOylation-related patterns in shaping the tumor microenvironment and predicting treatment sensitivity of colorectal cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SUMOylation is a critical post-translational modification that governs protein stability, subcellular localization, and signal transduction. Accumulating evidence suggests that dysregulated SUMOylation contributes to colorectal cancer (CRC) progression. However, its global impact on tumor microenvironment (TME) remodeling and clinical heterogeneity remains incompletely understood. The objective of this study was to establish a robust SUMOylation-related transcriptional signature to quantify SUMOylation activity in CRC and to elucidate its association with immune infiltration patterns, patient prognosis, and therapeutic responsiveness. Methods: Using integrated transcriptomic profiles from The Cancer Genome Atlas (TCGA) and multiple Gene Expression Omnibus (GEO) cohorts (total n=1,226), we systematically curated SUMOylation-related genes (SRGs) and developed a SUMOylation-based scoring system (SUMOscore). Patients were stratified into high and low SUMOscore subgroups, followed by comprehensive evaluation of clinical outcomes, tumor staging, stromal components, and immune-cell infiltration landscapes. Potential responses to immune checkpoint blockade (ICB) and 5-fluorouracil (5-FU) chemotherapy were further inferred using established computational frameworks. Results: Five key SRGs were identified to construct a scoring model that categorizes patients into high and low SUMOscore groups. The SUMOscore is an independent prognostic factor for CRC patients. Higher SUMOscore correlates with shorter overall survival (OS), advanced tumor staging, increased stromal infiltration, and lower tumor mutational burden. Further analysis suggests that CRC patients with lower SUMOscore might be more sensitive to immune checkpoint inhibitors and 5-FU chemotherapy. Conclusions: The SUMOscore captures clinically relevant TME heterogeneity in CRC and may help guide selection of immunotherapy and adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.